Skip to main content
Equibles
YCBD logo

YCBD · cbdMD, Inc.

Track YCBD — free

Use YCBD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about YCBD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.50 -0.07 (-12.25%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These and other factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that these financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$5.55M
Shares
11.21M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.50 Open$0.56 Day$0.49–0.58 52W close$0.47–2.27 Avg vol 30d245K Short int528K · 4.7% float · 2.6d Short vol12% Last earningsNov 25, 2025 DataMay 2025–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on May 7, 2025; bars on opposite sides are not compared.

Up next

FQ4-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −38%
below
Price vs 50-day avg −22%
below
RSI (14) 36
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −46%
trailing
YTD return −63%
this year
Relative strength −60%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.71% of float · ▼ -5.9% MoM · 2.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
27 holders — near 3-yr high, broad support
Squeeze score 48
elevated · 0–100
Fundamentals
Strong
Revenue growth −1%
Y/Y
Gross margin 62%
expanding
EPS growth +92%
Y/Y
Free cash flow $-1.6M
Balance sheet $2.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 196%
annualized · 1-yr
Max drawdown −79%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the 8-K filed Nov 25, 2025
Net sales revenue · fiscal 2025 $19.1M – $19.3M
Net sales revenue · fourth quarter of fiscal 2025 $4.7M – $4.9M
Net Loss · fiscal 2025 $1.9M – $2.1M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−38% Bearish
Price vs 50-day avg
−22% Bearish
RSI (14)
36 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.71% of float · ▼ -5.9% MoM · 2.6 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
27 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $2
vs 200-day avg -38% vs 50-day avg -22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
YCBD
cbdMD, Inc.
this stock
$5.55M -63.3% -1.5% — 4.7%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $64.91B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $56.30B +13.1% — — 0.1%
GALDY
Galderma Group AG/ADR
 $49.59B +2.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $42.85B +17.8% +4.3% 60.3 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
27
% held
8.2%
Net QoQ
-23.2K sh
Top holder
Worth Venture Partners, L…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
527.7K
Days to cover
2.6d
Change
-33.3K sh
View
Short Volume
Short vol %
12%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
9.6K
Value
$6.5K
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
71.6%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$19.2M
Net income (FY)
$-2.0M
EPS diluted
$-1.09
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 13, 2026
This year
9
View
Proposed Sales
Value
$2.2M
Shares
986.9K
Filed
Dec 17, 2025
View
Earnings & Events
Earnings Calls
Last call
Nov 25, 2025
View

Performance

Raw-price comparisons begin at the captured split on May 7, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
YCBD -12.3% -13.0% -45.9% -2.2% -63.3%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -12.7% -17.5% -59.7% -6.1% -77.1%
Key facts CIK 1644903 CUSIP 12482W408 13F (30d) 25 filings 25 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)